# Bioavailability of Two Combination Products of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) in Asian Males.

> **NCT01471678** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 27 (actual)

## Conditions studied

- Prostatic Hyperplasia

## Interventions

- **DRUG:** Dutasteride (0.5mg)
- **DRUG:** FDC product of dutasteride (0.5mg) and tamsulosin HCl (0.2mg)
- **DRUG:** Harnal D Tablets and Harnal Capsules (both comprising 0.2 mg tamsulosin HCl)

## Key facts

- **NCT ID:** NCT01471678
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06-30
- **Primary completion:** 2011-09-07
- **Final completion:** 2011-09-07
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2018-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01471678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01471678, "Bioavailability of Two Combination Products of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) in Asian Males.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01471678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*